Infinity Pharma INFI announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were ...
(RTTNews) - Infinity Pharmaceuticals Inc. (INFI) provided an update from its MARIO-3 study of eganelisib in combination with atezolizumab and nab-paclitaxel in front-line metastatic triple negative ...
Infinity Pharmaceuticals Inc (NASDAQ:INFI) announced further design features of its Phase 2 MARIO-8 study in Squamous Cell Cancer of the Head and Neck (SCCHN). The adaptive design of the MARIO-8 study ...
Like many Managed Service Providers (MSPs), Digital Infinity IT Group faced the operational challenge of managing email authentication across a diverse and growing client base. Configuring DMARC, DKIM ...
Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results